Haemonetics Corp. Reports Strong Q2 2026 Earnings and Receives Optimistic Price Target
Financial Performance
Haemonetics Corp. (NYSE: HAE) announced its second‑quarter fiscal 2026 results, covering the period ending September 27 2025. The company reported a 14.3 % increase in earnings, rising to $38.68 million from $33.83 million in the same quarter of the previous year. Earnings per share (EPS) also grew, reaching $0.81 versus $0.66 a year earlier, reflecting a 22.9 % rise. These figures are consistent with the company’s guidance and improve its outlook for the remainder of fiscal 2026.
Market Reaction
Following the earnings announcement, Haemonetics shares experienced a notable uptick. The stock closed at $50.72 on November 4 , 2025, positioning it within the lower portion of its 52‑week range (52‑week low: $47.32; 52‑week high: $94.99). The company’s market capitalization remains at $2.43 billion, and its price‑to‑earnings ratio is currently 15.49.
Analyst Sentiment
On November 6 , 2025, BTIG analyst Marie Thibault raised her price target for Haemonetics to $88. The upgrade reflects the analyst’s confidence in the company’s continued earnings growth and its strategic position in the health‑care equipment sector. The upgrade coincided with the release of the company’s Q2 results and a broader positive market reception.
Strategic Context
Haemonetics specializes in automated blood‑processing systems for surgical blood salvage, blood component collection, and plasma collection. The company markets its products globally and maintains a robust pipeline of technologies aimed at enhancing efficiency and safety in blood management. The recent earnings growth underscores the effectiveness of this strategy and supports the upward revision of the price target by BTIG.
Outlook
With a solid Q2 performance, an elevated analyst price target, and a clear focus on expanding its product portfolio, Haemonetics is positioned to capitalize on demand for advanced blood‑processing solutions. Investors and market observers will likely monitor the company’s subsequent quarterly results and any further guidance updates to assess whether the new price target is sustainable.
